2576
F. Zhang et al. / Bioorg. Med. Chem. Lett. 13 (2003) 2573–2576
174.2. (a) Rusconi, S.; Catamancio, S. Expert Opin. Investig.
Drugs 2002, 11, 387. (b) Vacca, J. P.; Condra, J. H. Drug Dis-
covery Today 1997, 2, 261.
2. (a) Rusconi, S.; Catamancio, S. Expert Opin. Investig.
Drugs 2002, 11, 387. (b) Vacca, J. P.; Condra, J. H. Drug Dis-
covery Today 1997, 2, 261.
3. Duffy, J. L.; Rano, T. A.; Kevin, N. J.; Chapman, K. T.;
Schleif, W. A.; Olsen, D. B.; Stahlhut, M.; Rutkowski, C. A.;
Kuo, L. C.; Jin, L.; Lin, J. H.; Emilio, E. A.; Tata, J. R.
Bioorg. Med. Chem. Lett. see preceding article in this issue.
doi:10.1016/S0960-894X(03)00475-X
4. Reider, P. J. Chimia 1997, 51, 306.
5. Harrowven, D. C.; Nunn, M. I. T. Tetrahedron Lett. 1998,
39, 5875.
9. Chiba, M.; Hensleigh, M.; Nishime, J. A.; Balani, S. K.;
Lin, J. H. Drug Metab. Disp. 1996, 24, 307.
10. Chiba, M.; Jin, L.; Neway, W; Vacca, J. P.; Tata,
J. R.; Chapman, K.; Lin, J. H. Drug Metab. Disp.
2001, 29, 1.
11. Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.;
Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N.
Drug Metab. Disp. 1998, 26, 552.
12. (a) Kumar, G. N.; Dykstra, J.; Roberts, E. M.; Jayanti,
V. K.; Hickman, D.; Uchic, J.; Yao, Y.; Surber, B.; Thomas,
S.; Granneman, G. R. Drug Metab. Disp. 1999, 27, 902. (b)
Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.;
Denissen, J. F.; Mcdonald, E.; Kukulka, M. J.; Hsu, A.;
Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Platt-
ner, J. J.; Norbeck, D. W.; Leonard, J. M. Antimicrob. Agents
Chemother. 1997, 41, 654. (c) Jin, L.; Chen, I. W.; Chiba, M.;
Lin, J. Xenobiotica, in press.
13. The use of animals was approved by Merck Research
Laboratories Institutional Animal Care and Use Committee
(IACUC), and all applicable regulations and laws pertaining
to the use of laboratory animals were followed. For experi-
mental methods for both in vitro and in vivo pharmacokinetic
investigations, see: Lin, J. H.; Chiba, M.; Balani, S. K.; Chen,
I.-W.; Kwei, G. Y.-S.; Vastag, K. J.; Nishime, J. A. Drug
Metab. Disp. 1996, 24, 1111.
14. Data forcompound 10. 1H NMR (CD3OD, 500 Hz) d
8.49 (s, 1H), 8.22 (d, J=1.6 Hz, 1H), 7.66–7.67 (m, 1H), 7.20–
7.25 (m, 4H), 7.14–7.17 (m, 1H), 7.06–7.10 (m, 2H), 6.80 (t,
J=7.6 Hz, 1H), 6.71 (d, J=8.0 Hz, 1H), 5.13 (d, J=3.8 Hz,
1H), 4.04–4.06 (m, 2H), 3.92–3.98 (m, 1H), 3.94 (s, 3H), 3.78–
3.82 (m, 1H), 3.72–3.77 (m, 2H), 3.06–3.10 (m, 1H), 2.96–3.03
(m, 2H), 2.88–2.94 (m, 1H), 2.85 (d, J=11.2 Hz, 1H), 2.70–
2.77 (m, 2H), 2.63–2.67 (m, 1H), 2.44–2.50 (m, 1H), 2.34–2.44
(m, 4H), 2.00–2.04 (m, 1H), 1.60 (s, 3H); LC-MS (M++1)
(EI) 781.5.
6. The epoxide VII may be synthesized in direct analogy to
the aminoindanol derivative: Maligres, P. E.; Upadhyay, V.;
Rossen, K.; Cianciosi, S. J.; Purick, R. M.; Eng, K. K.;
Reamer, R. A.; Askin, D.; Reider, P. J. Tetrahedron Lett.
1995, 36, 2195.
7. Vacca, J. P.; Dorsey, B. D.; Schleif, W. A.; Levin, R. B.;
McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.;
Blahy, O. M.; Roth, E.; Sardana, V. V.; Schlabach, A. J.;
Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.;
Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.;
Emini, E. A.; Huff, J. R. Proc. Nat. Acad. Sci. 1994, 91, 4096.
8. (a) Olsen, D. B.; Stahlhut, M. W.; Rutkowski, C. A.;
Schock, H. B.; vanOlden, A. L.; Kuo, L. C. J. Biol. Chem.
1999, 274, 23699. (b) Condra, J. H.; Holder, D. J.; Schleif,
W. A.; Blahy, O. M.; Danovich, R. M.; Gabyelski, L. J.;
Graham, D. J.; Laird, D.; Quintero, J. C.; Rhodes, A.; Rob-
bins, H. L.; Roth, E.; Shivaprakash, M.; Yang, T.; Chodake-
witz, J. A.; Deutsch, P. J.; Leavitt, R. Y.; Massari, F. E.;
Mellors, J. W.; Squires, K. E.; Steigbigel, R. T.; Teppler, H.;
Emini, E. A. J. Virol. 1996, 70, 8270. (c) Schock, H. B.;
Garsky, V. M.; Kuo, L. C. J. Biol. Chem. 1996, 271, 31957.